Pacific Biosciences of California Inc (NASDAQ: PACB) on Friday, soared 20.62% from the previous trading day, before settling in for the closing price of $1.94. Within the past 52 weeks, PACB’s price has moved between $0.85 and $2.72.
A company in the Healthcare sector has dropped its sales by -23.55% annually for the last half of the decade. The company achieved an average annual earnings per share of -67.14%. With a float of $266.29 million, this company’s outstanding shares have now reached $300.35 million.
In an organization with 575 employees, it is important to assess its efficiency.
Pacific Biosciences of California Inc (PACB) Insider and Institutional Ownership
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Pacific Biosciences of California Inc is 11.35%, while institutional ownership is 59.83%. The most recent insider transaction that took place on Aug 18 ’25, was worth 35,182. In this transaction an insider of this company sold 26,836 shares at a rate of $1.31, taking the stock ownership to the 1,920,035 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 26,836 for $1.31, making the entire transaction worth $35,174.
Pacific Biosciences of California Inc (PACB) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.17 earnings per share (EPS) for the period topping the consensus outlook (set at -0.21) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.21% during the next five years compared to -23.55% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Pacific Biosciences of California Inc (PACB) is currently performing well based on its current performance indicators. A quick ratio of 6.02 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Let’s dig in a bit further. During the last 5-days, its volume was 12.12 million. That was better than the volume of 9.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.30%.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 97.60%, which indicates a significant increase from 96.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was higher than the 0.11 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.49, while its 200-day Moving Average is $1.36. However, in the short run, Pacific Biosciences of California Inc’s stock first resistance to watch stands at $2.46. Second resistance stands at $2.57. The third major resistance level sits at $2.78. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $1.93. The third support level lies at $1.82 if the price breaches the second support level.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
Market capitalization of the company is 702.87 million based on 300,371K outstanding shares. Right now, sales total 154,010 K and income totals -309,850 K. The company made 39,770 K in profit during its latest quarter, and -41,930 K in sales during its previous quarter.
